Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed epithelial carcinoma arising in the ovary, fallopian tube, or peritoneum
• •* Any stage and grade at diagnosis
• •Must have received initial cytoreductive surgery and chemotherapy with ≥ 1 platinum-based chemotherapy regimen
• •* Persistent or recurrent disease after initial therapy
• •In complete clinical remission after chemotherapy for recurrent disease, meeting all of the following criteria:
• •* CA125 ≤ 35 units/L
• •* Normal physical examination
• •* No definite evidence of disease by CT scan of the abdomen and pelvis
• •* Lymph nodes and/or soft tissue abnormalities ≤ 1.0 cm are not considered definite evidence of disease
• •No known brain metastases
• •PATIENT CHARACTERISTICS:
• •Karnofsky performance status 70-100%
• •Life expectancy \> 3 months
• •ANC ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Hemoglobin ≥ 9.0 g/dL
• •INR \< 1.5 OR PT/PTT within normal limits
• •Creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Urinalysis negative for protein
• •* If urinalysis shows 1+ protein by dipstick or protein ≥ 30-100 mg/dL by semi-quantitative assay, a 24-hour urine collection is required
• •* Eligible patients must have a total urinary protein ≤ 500 mg AND measured creatinine clearance ≥ 50 mL/min from a 24-hour urine collection
• •Bilirubin ≤ 1.5 times ULN
• •AST and ALT ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •Stable blood pressure (BP) measurement required on 3 separate days prior to the start of treatment
• •No peripheral neuropathy \> grade 1
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •See Disease Characteristics
• •No prior sorafenib tosylate or other inhibitors of MAPK signaling intermediates or angiogenesis inhibitors
• •No prior cancer treatment that would contraindicate protocol therapy
• •More than 4 weeks since prior radiotherapy
• •More than 3 weeks since prior chemotherapy, biological therapy, or immunotherapy
• •More than 1 week since prior hormonal therapy for cancer treatment